Literature DB >> 31471787

External validation of a postoperative nomogram for the prediction of disease-specific survival in patients with papillary renal cell carcinoma using a large multicenter database.

Stefan Zastrow1,2, Laura-Maria Krabbe3, Ingmar Wolff4, Umberto Capitanio5,6, Tobias Klatte7, Thorsten Ecke8, Nina Huck9, Hendrik Borgmann10, Anna Scavuzzo11, Luca Cindolo12, Luigi Schips13, Cristian Surcel14, Cristian Mirvald14, Antoni Vilaseca Cabo15, Mireia Musquera15, Georg Hutterer16, Kristyna Prochazkova17, Christian Stief18, Manfred Wirth19,20, Matthias May21, Sabine Brookman-May18.   

Abstract

PURPOSE: Based on data retrieved from a comprehensive multicenter database, we externally validated a published postoperative nomogram for the prediction of disease-specific survival (DSS) in patients with papillary renal cell carcinoma (papRCC).
METHODS: A multicenter database containing data of 2325 patients with surgically treated papRCC was used as validation cohort. After exclusion of patients with missing data and patients included in the development cohort, 1372 patients were included in the final analysis. DSS-probabilities according to the nomogram were calculated and compared to actual DSS-probabilities. Subsequently, calibration plots and decision curve analyses were applied.
RESULTS: The median follow-up was 38 months (IQR 11.8-80.7). Median DSS was not reached. The c-index of the nomogram was 0.71 (95% CI 0.60-0.83). A sensitivity analysis including only patients operated after 1998 delivered a c-index of 0.84 (95% CI 0.77-0.92). Calibration plots showed slight underestimation of nomogram-predicted DSS in probability ranges below 90%: median nomogram-predicted 5-year DSS in the range below 90% was 55% (IQR 20-80), but the median actual 5-year DSS in the same group was 58% (95% CI 52-65). Decision-curve analysis showed a positive net-benefit for probability ranges between a DSS probability of 5% and 85%.
CONCLUSIONS: The nomogram performance was satisfactory for almost all DSS probabilities; hence it can be recommended for application in clinical routine and for counseling of patients with papRCC.

Entities:  

Keywords:  Nomogram; Papillary; Prognosis; Renal cell carcinoma

Mesh:

Year:  2019        PMID: 31471787     DOI: 10.1007/s10147-019-01530-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  11 in total

1.  Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma.

Authors:  Tobias Klatte; Mesut Remzi; Richard E Zigeuner; Sebastian Mannweiler; Jonathan W Said; Fairooz F Kabbinavar; Andrea Haitel; Matthias Waldert; Michela de Martino; Michael Marberger; Arie S Belldegrun; Allan J Pantuck
Journal:  J Urol       Date:  2010-05-15       Impact factor: 7.450

2.  Fuhrman grading is inappropriate for papillary renal cell carcinoma.

Authors:  Brett Delahunt; Lars Egevad; John R Srigley; Hemamali Samaratunga
Journal:  World J Urol       Date:  2017-12-18       Impact factor: 4.226

3.  Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience.

Authors:  Jean-Jacques Patard; Emmanuelle Leray; Nathalie Rioux-Leclercq; Luca Cindolo; Vincenzo Ficarra; Amnon Zisman; Alexandre De La Taille; Jacques Tostain; Walter Artibani; Claude C Abbou; Bernard Lobel; François Guillé; Dominique K Chopin; Peter F A Mulders; Christopher G Wood; David A Swanson; Robert A Figlin; Arie S Belldegrun; Allan J Pantuck
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

Review 4.  The Heidelberg classification of renal cell tumours.

Authors:  G Kovacs; M Akhtar; B J Beckwith; P Bugert; C S Cooper; B Delahunt; J N Eble; S Fleming; B Ljungberg; L J Medeiros; H Moch; V E Reuter; E Ritz; G Roos; D Schmidt; J R Srigley; S Störkel; E van den Berg; B Zbar
Journal:  J Pathol       Date:  1997-10       Impact factor: 7.996

5.  Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study.

Authors:  Sandra Steffens; Martin Janssen; Frederik C Roos; Frank Becker; Simon Schumacher; Christoph Seidel; Gerd Wegener; Joachim W Thüroff; Rainer Hofmann; Michael Stöckle; Stefan Siemer; Mark Schrader; Arndt Hartmann; Markus A Kuczyk; Kerstin Junker; Andres J Schrader
Journal:  Eur J Cancer       Date:  2012-06-13       Impact factor: 9.162

Review 6.  Follow-up after curative treatment of localised renal cell carcinoma.

Authors:  Saeed Dabestani; Lorenzo Marconi; Teele Kuusk; Axel Bex
Journal:  World J Urol       Date:  2018-05-16       Impact factor: 4.226

7.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

Review 8.  Prognostic factors and prognostic models for renal cell carcinoma: a literature review.

Authors:  Tobias Klatte; Sabrina H Rossi; Grant D Stewart
Journal:  World J Urol       Date:  2018-04-30       Impact factor: 4.226

Review 9.  WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies.

Authors:  Anne Y Warren; David Harrison
Journal:  World J Urol       Date:  2018-08-19       Impact factor: 4.226

10.  Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers.

Authors:  Andrew J Vickers; Angel M Cronin; Elena B Elkin; Mithat Gonen
Journal:  BMC Med Inform Decis Mak       Date:  2008-11-26       Impact factor: 2.796

View more
  2 in total

1.  The first competing risk survival nomogram in patients with papillary renal cell carcinoma.

Authors:  Xing Su; Niu-Niu Hou; Li-Jun Yang; Peng-Xiao Li; Xiao-Jian Yang; Guang-Dong Hou; Xue-Lin Gao; Shuai-Jun Ma; Fan Guo; Rui Zhang; Wu-He Zhang; Wei-Jun Qin; Fu-Li Wang
Journal:  Sci Rep       Date:  2021-06-04       Impact factor: 4.379

2.  lncRNA 00312 Attenuates Cell Proliferation and Invasion and Promotes Apoptosis in Renal Cell Carcinoma via miR-34a-5p/ASS1 Axis.

Authors:  Jiawei Zeng; Yuanmeng Li; Yaodong Wang; Gang Xie; Qian Feng; Yuwei Yang; Jiafu Feng
Journal:  Oxid Med Cell Longev       Date:  2020-03-23       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.